Endocrinological manifestations in RASopathies. Issue 4 (19th November 2022)

• Record Type: Journal Article
• Authors: Tamburrino, Federica; Scarano, Emanuela; Schiavariello, Concetta; Perri, Annamaria; Pession, Andrea; Mazzanti, Laura
• Other Names: Leoni Chiara guestEditor.; Neri Giovanni guestEditor.
• Is Part Of: American journal of medical genetics. Volume 190:Issue 4(2022)
• Page Start: 471
• Page End: 477
• Publication Date: 2022-11-19
• Subjects: growth -- growth hormone therapy -- Noonan syndrome -- puberty -- RASopathies -- thyroid function; Medical genetics -- Periodicals; 616.04205
• DOI: 10.1002/ajmg.c.32013
• Languages: English
• ISSNs: 1552-4868

Abstract

Abstract: The evaluation of endocrine involvement in RASopathies is important for the care and follow‐up of patients affected by these conditions. Short stature is a cardinal feature of RASopathies and correlates with multiple factors. Growth hormone treatment is a therapeutic possibility to improve height and quality of life. Assessment of growth rate and growth laboratory parameters is routine, but age at start of therapy, dose and effects of growth hormone on final height need to be clarified. Puberty disorders and gonadal dysfunction, in particular in males, are other endocrinological areas to evaluate for their effects on growth and development. Thyroid dysfunction, autoimmune disease and bone involvement have also been reported in RASopathies. In this brief review, we describe the current knowledge on growth, growth hormone therapy, endocrinological involvement in patients affected by RASopathies.